Aytu BioPharma Q3 2026 earnings reveal $12.4M revenue, $2.4M from EXUA launch, and strong prescriber adoption. Learn more here.

Key Takeaways

• Net revenue for Q3 2026 was $12.4 million, a 33% decrease year-over-year from $18.5 million.
• The company’s new product, EXUA, generated $2.4 million in revenue during the quarter, with over 1,300 prescriptions written.
• Gross profit margin decreased to 61%, impacted by a $700,000 inventory write-down.
• More than 450 unique prescribers wrote prescriptions for EXUA, indicating strong early adoption.
• The company reported a net loss of $5.6 million, or $0.53 per share, compared to a net income of $4 million in Q3 2025.

Financial Performance

Aytu BioPharma, Inc. reported its third-quarter earnings for fiscal 2026, reflecting both the challenges and opportunities facing the company as it transitions to a focus on its newly launched product, EXUA. The company's net revenue reached $12.4 million, down from $18.5 million in the same quarter last year, indicating a 33% year-over-year decline. This decrease is primarily attributed to a strategic shift in the sales force’s focus towards EXUA, as well as the introduction of generic competition impacting legacy products.

The revenue from EXUA, which was only recently launched, contributes positively to the overall revenue picture. EXUA brought in $2.4 million during the quarter, demonstrating the potential for growth despite the initial challenges. Notably, the gross profit margin decreased to 61%, down from 69% in the previous year, partly due to an inventory write-down. However, excluding this write-down, the gross margin would have been approximately 67%.

Strategic Initiatives

The recent earnings call highlighted the company's strategic initiatives surrounding the commercial launch of EXUA, a selective serotonin 5-HT1A receptor agonist aimed at treating major depressive disorder (MDD). The product was made commercially available in mid-December 2025, with a more formal launch following in January 2026. The deployment of the full sales force, which consists of over 40 representatives, began in late February 2026.

The company reported encouraging early adoption metrics: over 1,300 prescriptions for EXUA were written during the quarter, with a growth trajectory that saw monthly prescriptions increase from about 200 in January to over 700 in March. This sequential growth is significant, reflecting a 26% month-over-month increase in prescription counts in April, underscoring a positive reception from healthcare providers.

Importantly, the breadth of prescriber adoption is encouraging, with more than 450 unique prescribers engaging with EXUA, representing 10-13% of the targeted prescriber universe. Aytu's sales strategy emphasizes disciplined engagement with high-value psychiatric practices, which is critical for building a solid foundation for the product's future growth.

Future Outlook

Looking ahead, management remains optimistic about EXUA's market potential. The company's strategy includes increasing prescriber calls and leveraging its RX Connect program to facilitate patient access to the medication. RX Connect aims to reduce friction for prescribers and patients by providing a no-cost 14-day titration pack and guaranteeing coverage for the first two months of therapy, which is crucial for patients with MDD.

With ongoing investments in scientific engagement and medical education, Aytu aims to enhance EXUA's visibility among healthcare providers. Management indicated that they plan to ramp up online promotional campaigns, which will likely increase marketing expenditures in the upcoming quarters. The expectation is that as awareness grows, so will prescription volumes, leading to improved revenue metrics.

While the company did not provide formal revenue guidance, the early results from EXUA and the strategic focus on reducing access barriers provide a framework for future growth. The management team's disciplined approach to investment and spending aligns with performance metrics and cash flow generation from legacy products, ensuring that Aytu remains well-positioned financially as it navigates this transitional phase.

In summary, the company’s strategic focus on the launch of EXUA, along with the solid early adoption metrics, paints an optimistic picture for Aytu BioPharma. With the ongoing commitment to disciplined investment and a focus on expanding prescriber engagement, Aytu appears to be on a promising trajectory within the MDD treatment landscape.

Overall, while challenges remain, Aytu's proactive strategies could lead to significant growth opportunities in the future.

This analysis is based on public earnings call materials and is not investment advice.